Novo Nordisk CagriSema cuts blood pressure, heart disease risk, shows anti-inflammatory effect

Novo Nordisk (NVO) presented post hoc REDEFINE 1 analyses at ObesityWeek (Nov 6, 2025) showing investigational CagriSema (2.4 mg/2.4 mg) reduced systolic blood pressure by 10.9 mmHg versus 8.8 mmHg for semaglutide 2.4 mg and 2.1 mmHg for placebo over 68 weeks.

CagriSema allowed ~40% of participants on antihypertensives to reduce or stop medication and lowered hsCRP by 68.9% (versus 55.4% semaglutide, 16.0% placebo). Safety was consistent with the GLP-1 RA class; gastrointestinal adverse events were more frequent with CagriSema.

https://www.stocktitan.net/news/NVO/novo-nordisk-s-cagri-sema-was-associated-with-significant-reduction-lzv8wvs9985i.html